RT Journal Article
SR Electronic
T1 Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3725
OP 3729
VO 36
IS 7
A1 MIYAHARA, DAISUKE
A1 KATSUTA, TAKAHIRO
A1 MAEHARA, MIYAKO
A1 TAKAHASHI, YOKO
A1 FUKAGAWA, SATOSHI
A1 MIYATA, KOUHEI
A1 KIYOSHIMA, CHIHIRO
A1 YOTSUMOTO, FUSANORI
A1 ANAN, HARUCHIKA
A1 MIYAMOTO, SHINGO
YR 2016
UL http://ar.iiarjournals.org/content/36/7/3725.abstract
AB Background: Endometrial cancer (EC) has a poor prognosis due to drug resistance. Patients and Methods: We evaluated the safety and efficacy of adjuvant combination chemotherapy with docetaxel plus cisplatin ((DP) docetaxel, 70 mg/m2; cisplatin, 60 mg/m2; every 28 days) in EC patients at intermediate-risk (IR) or high-risk (HR) for recurrence. Results: Sixty-four patients diagnosed with EC were enrolled. Stage-I, -II, -III and -IV disease was noted in 23, 7, 28 and 6 patients, respectively. Histopathological analyses revealed that 56, 3, 1 and 4 patients had endometrioid, serous, clear-cell or “other” types of carcinoma. Grade-3/4 hematologic toxicities were found at 80% and 95% in patients in IR and HR groups, respectively. In IR and HR groups, mean progression-free (PFS) survival was 69.5 and 29.5, while overall survival (OS) was 59.6 and 47.5 months, respectively. Conclusion: DP may be clinically safe and useful treatment for EC.